<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223713</url>
  </required_header>
  <id_info>
    <org_study_id>77/19-S</org_study_id>
    <nct_id>NCT04223713</nct_id>
  </id_info>
  <brief_title>4D- Flow- MRI After Aortic Valve Surgery</brief_title>
  <official_title>Changes of Aortic Flow Patterns Detected by 4D- Flow- MRI After Trileaflet Reconstruction of the Aortic Valve With Autologous Pericardium Compared to Prosthetic Valve Replacement With Biological Prosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial was designed to analyze flow patterns in the ascending aorta
      with MRI after either Trileaflet reconstruction of the aortic valve with autologous
      pericardium (TriRec) or surgical valve replacement with biological prosthesis. The hypothesis
      is that after TriRec procedure more physiological flow patterns will be observed, compared to
      biological valve prosthesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trileaflet reconstruction of the aortic valve with autologous pericardium (TriRec) is a new
      treatment option for diseased aortic valves and offers benefits compared to conventional
      valve replacement. At the moment no prospective randomized trials evaluating the role of the
      TriRec procedure are available and factors contributing to long- term durability are unknown.

      The investigators want to examine aortic flow patterns with 4D- Flow- Magnetic Resonance
      Imaging (MRI) in patients after the TriRec procedure or biological prosthetic valve
      replacement in a prospective randomized trial. Flow patterns in the ascending aorta, examined
      with 4D- Flow- MRI, show nearly laminar flow patterns and no outflow obstruction in healthy
      subjects with tricuspid aortic valves. In contrast, helical flow patterns, turbulences and
      increased flow velocities are observed in diseased valves and also after valve replacement
      with mechanical or biological prostheses. These helical flow patterns seem to influence
      aortic wall remodeling and may contribute to structural valve dysfunction of biological
      prosthesis.

      The investigators hypothesize that after TriRec procedure more physiological flow patterns
      will be observed, compared to biological valve prosthesis. The results can contribute to
      understand mechanisms for long- term performance of this technique and determine the role of
      this novel technique for treatment of aortic valve disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow velocity in the ascending aorta (m/s)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Flow velocity in meters/ second in the ascending aorta in patients receiving either TriRec or biological prosthetic valve replacement measured by 4D- Flow- MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow vortices</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Flow vortices: defined as rotating particles around a point within the vessel with the rotational direction diverting &gt; 90Â° from the physiological flow direction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow helicality</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Blood revolving around an axis parallel to the main blood flow generating a corkscrew like figure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic eccentricity</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Localization of the main blood flow vector (central, little, severe eccentricity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow patterns in the left ventricular outflow tract.</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Flow patterns in the left ventricular outflow tract.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective orifice area (4D-Flow-MRI)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Effective orifice area (cm2) of the reconstructed or replaced valve (4D- Flow- MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective orifice area (TTE)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Effective orifice area (cm2) of the reconstructed or replaced valve (transthoracic echocardiography (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak- and mean pressure gradients (mmHg, TTE)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Peak- and mean pressure gradients (mmHg, TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left- ventricular diameters (mm, TTE)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Left- ventricular diameters (mm, TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left- ventricular ejection fraction (%, TTE)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Left- ventricular ejection fraction (%, TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of aortic regurgitation (MRI)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Quantification of aortic regurgitation (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of aortic regurgitation (TTE)</measure>
    <time_frame>Day 4-7 post surgery</time_frame>
    <description>Quantification of aortic regurgitation (TTE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>TriRec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trileaflet Reconstruction of the Aortic Valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic valve replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological prosthesis, Device: St. Jude Medical Trifecta GT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TriRec</intervention_name>
    <description>Trileaflet Reconstruction of the Aortic Valve</description>
    <arm_group_label>TriRec</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aortic valve replacement</intervention_name>
    <description>Biological Prosthesis, Device: St. Jude Medical Trifecta GT</description>
    <arm_group_label>Aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 50 years

          -  Documented symptomatic moderate or greater aortic stenosis or severe aortic
             insufficiency

          -  Aortic annulus &gt; 19 mm

          -  Written informed consent of the patients.

        Exclusion Criteria:

          -  Concomitant intervention of the aortic root, ascending aorta or aortic arch

          -  Concomitant valve surgery

          -  Emergency surgery for any reason

          -  Neurological events (i.e. stroke, TIA) within the previous 6 months

          -  Coagulation disorders (including thrombocytopenia &lt; 100.000/ml)

          -  Porcelain aorta/severe calcification of the ascending aorta

          -  Active endocarditis or other active systemic infections

          -  Participating in another trial that may influence the outcome of this trial

          -  Pregnancy

          -  Dual antiplatelet therapy

          -  Previous cardiac surgery (excluding percutaneous procedures)

          -  Contraindication for MRI- examinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anatol Prinzing, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>2777</phone_ext>
    <email>prinzing@dhm.mhn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen, Department of Cardiovascular Surgery</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anatol Prinzing, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic regurgitation</keyword>
  <keyword>Trileaflet reconstruction of the aortic valve</keyword>
  <keyword>Biological aortic valve prosthesis</keyword>
  <keyword>aortic flow patterns</keyword>
  <keyword>MRI</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

